Finch Therapeutics Group, Inc. (FNCH)
| Market Cap | 18.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.17M |
| Shares Out | 1.61M |
| EPS (ttm) | -8.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 11.75 |
| Previous Close | 11.75 |
| Day's Range | 11.75 - 11.75 |
| 52-Week Range | 0.80 - 14.26 |
| Beta | 1.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboratio... [Read more]
Financial Performance
In 2023, Finch Therapeutics Group's revenue was $107,000, a decrease of -87.57% compared to the previous year's $861,000. Losses were -$74.75 million, -34.80% less than in 2022.
Financial StatementsNews
Finch Therapeutics looks to delist from the Nasdaq Global Select Market
Finch Therapeutics notifies Nasdaq of intent to delist shares, expects trading to continue on OTC market.
Finch Announces Delisting from Nasdaq and SEC Deregistration
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microb...
Finch Announces Reverse Stock Split of Common Stock
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectu...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of ...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio o...
Finch Therapeutics: Why This Finch Could Fly - An Asymmetric Risk/Reward Opportunity
Finch Therapeutics recently made the decision to discontinue the company's Phase 3 trial, lay off 95% of its workforce, and pursue the next path to maximize value for shareholders. As of now, the comp...
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio o...
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRI...
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH
NEW YORK , March 26, 2022 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Finch Therapeutics Group, Inc. ("Finch" or the "Company") (NASDAQ: FNCH). Such investors are a...
See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial
The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ: FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI).
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company lev...
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics Announces Additions to Senior Leadership Team
SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hu...
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile in...